Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity

7 May 2015

Abstract excerpt

RIG-I-like receptors are the key cytosolic sensors for RNA viruses and induce the production of type I interferons (IFN) and pro-inflammatory cytokines through a sole adaptor IFN-β promoter stimulator-1 (IPS-1) (also known as Cardif, MAVS and VISA) in antiviral innate immunity. These sensors also have a pivotal role in anticancer activity through induction of apoptosis. However, the mechanism for their anticancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Cytokine Signaling Pathways and Interactions
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25950488
DOI: 10.1038/cddis.2015.122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activityPMID 25950488Read ↗

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cellsSemantic proximity Read ↗

The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against CancerSemantic proximity Read ↗

Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAsSemantic proximity Read ↗

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanomaSemantic proximity Read ↗

Activation of the MDA-5–IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor ImmunitySemantic proximity Read ↗

A modified oncolytic measles virus exhibits strong immunotherapeutic potential through RIG-I activation by defective viral genomesSemantic proximity Read ↗

Tumor cell intrinsic RIG-I activation co-opts the host microenvironment to drive immune mediated tumor rejectionSemantic proximity Read ↗

PARP inhibitors enhance reovirus-mediated cell killing through the death-inducing signaling complex (DISC) with an associated NF-κB-regulated immune responseSemantic proximity Read ↗

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunitySemantic proximity Read ↗

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockadeSemantic proximity Read ↗

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.Semantic proximity Read ↗

Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I–driven cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.